Key points from article :
Mogrify secures $10m for Series A, bringing total to $46m, driving in vivo cellular reprogramming therapies.
Mogrify's technology enables direct in vivo transdifferentiation between any source cell type and any target cell type of clinical interest.
This capability is potentially beneficial in addressing degenerative diseases, particularly those affecting the eye, ear, and pancreas.
Mogrify's goal is to restore clinically valuable cell types within the patient's body, targeting conditions such as vision loss, hearing loss, and diabetes.
The $46m Series A funding will be used to advance Mogrify's pipeline of in vivo cellular reprogramming therapies and pave the way for first-in-human studies.
The new funding will also support various aspects of the company's operations, including pre-clinical translation, platform optimisation, and the facilitation of both new and existing biopharma collaborations.
